Skip to main content
    NanoViricides

    • Bind • Encapsulate • Destroy

      INNOVATIVE VIRAL THERAPEUTICS

      Broad-spectrum nanoviricides have been created that can bind to possibly as many as 90-95% of 
      known viruses. The Company is developing broad-spectrum nanoviricides to combat several 
      diseases:  NV-387 combats RSV, COVID-19, Flu and Smallpox; NV-HHV-1 combats Shingles and 
      others in the Herpes Family;  other Nanoviricides® combat other diseases like Dengue, Rabies, and 
      Ebola/Marburg. This versatility is similar to antibiotics such as penicillin that exploit a feature common 
      to all bacteria when they cure any bacterial infection.
      Read More

    Novel anti-viral could boost a US$3 bln market
    Proactive Research

    Nanoviricides Investigates NV-387 for MPOX Treatment Amid Global Outbreak


    Sept. 9, 2024

    How NanoViricides is Overcoming Challenges to the Current Model


    October 11, 2024

    The Wall Stree Transcirpt

    NanoViricides, Inc

    Bird flu is coming to humans...

    this treatment is ready!

    Press Releases

    NanoViricides Product Pipeline

    COVID

    Sars-Coronavirus
    MERS

    RSV

    SMALLPOX

     VZV "SHINGLES

    DERMAL TOPICAL

    CREAM

    HSV -1

    "GENITAL LESIONS"

    HSV-2

    "COLD SORES"

    HIVCIDE

    Potentially

    "Functional Cure"

    EBOLA, MARBURG,
    HEMORRHAGIC
    VIRUSES
    DENGUE VIRUS

    RABIES

    HEPATITIS C
    MANY MORE
    TO COME

    Company Fact Sheet

    A New Era in Targeted Anti-Viral Therapeutics
    Imagine coursing through the blood stream, chasing through the body, grabbing and destroying the offending virus particles. NanoViricides, Inc. is striving to bring this imagination to fruition. A nanoviricide®, as defined by the Company, is a nanomachine that is armed to destroy a particular kind of virus. Which virus? That information is programmed into the nanoviricide, akin to the postal address on an envelope.
    Biomimetic Technology to "Fool" Viruses
    A "nanoviricide" is an agent designed by the Company to fool a virus into attaching to this antiviral nanomachine, in the same way that the virus normally attaches to the receptors on a cell surface. Once attached, the flexible nanoviricide glob wraps around the virus and traps it. In the process, the virus also loses its coat proteins that it needs to bind to a cell. The virus is thus neutralized and effectively destroyed. A nanoviricide completes the task of dismantling the virus particle without immune system assistance. This is the putative or designed mechanism of action of a nanoviricide. Thus nanoviricides represent the next great advance in "Immunotherapeutics" (antibodies and vaccines), which are currently well established antiviral strategies.
    Anil R. Diwan
    Executive Chairman, President
    Dr. Diwan invented novel polymeric micelle-based nanomedicine technologies
    More at Officers & Board

    Meeta Vyas

    Chief Financial Officer

    Ms. Vyas was First Indian woman to be named CEO of a publicly listed US corporation

    More at Officers & Board


    Randall Barton
    Chief Scientific Officer - Consulting
    Dr. Barton has over 25 years experience in drug discovery and development
    More at Officers & Board
    Jayant Tatake
    Vice President, R&D
    Jay Tatake has over 25 years of experience in Organic Chemistry, Research and Process Development.
    More at Officers & Board